Metabolic and receptor imaging in patients with neuroendocrine tumors: Comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide

Martina L. Zalom, Alan D. Waxman, Run Yu, Jessica Lee, Grace Ih, Edward M. Wolin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To determine whether positron emission tomography/computed tomography (PET/CT) and indium In 111 pentetreotide, individually or collectively, predict the outcome of patients with neuroendocrine tumors (NETs). Methods: Between July 31, 2002, and May 4, 2007, 29 patients with previously diagnosed NETs underwent both PET/CT and indium In 111 pentetreotide imaging at our institution. The images were evaluated for the presence of abnormalities. Clinical outcomes were classified as survival without major morbidities, survival with severe complications of disease, or death. Time to outcome was measured in months from the imaging date to outcome. Kaplan-Meier survival curves were calculated in which patient outcome was compared with results on PET/CT and indium In 111 pentetreotide imaging. Results: Of the 29 patients, 9 had abnormalities on both PET/CT and indium In 111 pentetreotide imaging. Two patients had abnormal findings on PET/CT but normal findings on pentetreotide imaging. In 5 patients, findings were normal on PET/CT but abnormal on pentetreotide imaging. In 13 patients, normal findings were noted on both PET/CT and pentetreotide imaging. Kaplan-Meier analysis demonstrated a significant survival advantage for patients who had normal findings on PET/CT in comparison with abnormal PET/CT findings (P = .01). Patients with normal findings on indium In 111 pentetreotide imaging had a higher but insignificant survival advantage over those with abnormal results on pentetreotide imaging (P = .08). Conclusion: For evaluation of NETs, PET/CT and indium In 111 pentetreotide are complementary. Increased metabolic activity in tumor cells is reflected by abnormalities on PET/CT. Patients who had abnormal PET/CT findings had a generally poorer prognosis and a more rapid clinical deterioration than those with normal PET/CT findings.

Original languageEnglish (US)
Pages (from-to)521-527
Number of pages7
JournalEndocrine Practice
Volume15
Issue number6
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Survival
Kaplan-Meier Estimate
Positron Emission Tomography Computed Tomography
pentetreotide

ASJC Scopus subject areas

  • Endocrinology
  • Medicine(all)
  • Endocrinology, Diabetes and Metabolism

Cite this

Metabolic and receptor imaging in patients with neuroendocrine tumors : Comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide. / Zalom, Martina L.; Waxman, Alan D.; Yu, Run; Lee, Jessica; Ih, Grace; Wolin, Edward M.

In: Endocrine Practice, Vol. 15, No. 6, 09.2009, p. 521-527.

Research output: Contribution to journalArticle

Zalom, Martina L. ; Waxman, Alan D. ; Yu, Run ; Lee, Jessica ; Ih, Grace ; Wolin, Edward M. / Metabolic and receptor imaging in patients with neuroendocrine tumors : Comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide. In: Endocrine Practice. 2009 ; Vol. 15, No. 6. pp. 521-527.
@article{5b329e3a7af14fbab0b908c7738d5b7c,
title = "Metabolic and receptor imaging in patients with neuroendocrine tumors: Comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide",
abstract = "Objective: To determine whether positron emission tomography/computed tomography (PET/CT) and indium In 111 pentetreotide, individually or collectively, predict the outcome of patients with neuroendocrine tumors (NETs). Methods: Between July 31, 2002, and May 4, 2007, 29 patients with previously diagnosed NETs underwent both PET/CT and indium In 111 pentetreotide imaging at our institution. The images were evaluated for the presence of abnormalities. Clinical outcomes were classified as survival without major morbidities, survival with severe complications of disease, or death. Time to outcome was measured in months from the imaging date to outcome. Kaplan-Meier survival curves were calculated in which patient outcome was compared with results on PET/CT and indium In 111 pentetreotide imaging. Results: Of the 29 patients, 9 had abnormalities on both PET/CT and indium In 111 pentetreotide imaging. Two patients had abnormal findings on PET/CT but normal findings on pentetreotide imaging. In 5 patients, findings were normal on PET/CT but abnormal on pentetreotide imaging. In 13 patients, normal findings were noted on both PET/CT and pentetreotide imaging. Kaplan-Meier analysis demonstrated a significant survival advantage for patients who had normal findings on PET/CT in comparison with abnormal PET/CT findings (P = .01). Patients with normal findings on indium In 111 pentetreotide imaging had a higher but insignificant survival advantage over those with abnormal results on pentetreotide imaging (P = .08). Conclusion: For evaluation of NETs, PET/CT and indium In 111 pentetreotide are complementary. Increased metabolic activity in tumor cells is reflected by abnormalities on PET/CT. Patients who had abnormal PET/CT findings had a generally poorer prognosis and a more rapid clinical deterioration than those with normal PET/CT findings.",
author = "Zalom, {Martina L.} and Waxman, {Alan D.} and Run Yu and Jessica Lee and Grace Ih and Wolin, {Edward M.}",
year = "2009",
month = "9",
doi = "10.4158/EP08318.ORR1",
language = "English (US)",
volume = "15",
pages = "521--527",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "6",

}

TY - JOUR

T1 - Metabolic and receptor imaging in patients with neuroendocrine tumors

T2 - Comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide

AU - Zalom, Martina L.

AU - Waxman, Alan D.

AU - Yu, Run

AU - Lee, Jessica

AU - Ih, Grace

AU - Wolin, Edward M.

PY - 2009/9

Y1 - 2009/9

N2 - Objective: To determine whether positron emission tomography/computed tomography (PET/CT) and indium In 111 pentetreotide, individually or collectively, predict the outcome of patients with neuroendocrine tumors (NETs). Methods: Between July 31, 2002, and May 4, 2007, 29 patients with previously diagnosed NETs underwent both PET/CT and indium In 111 pentetreotide imaging at our institution. The images were evaluated for the presence of abnormalities. Clinical outcomes were classified as survival without major morbidities, survival with severe complications of disease, or death. Time to outcome was measured in months from the imaging date to outcome. Kaplan-Meier survival curves were calculated in which patient outcome was compared with results on PET/CT and indium In 111 pentetreotide imaging. Results: Of the 29 patients, 9 had abnormalities on both PET/CT and indium In 111 pentetreotide imaging. Two patients had abnormal findings on PET/CT but normal findings on pentetreotide imaging. In 5 patients, findings were normal on PET/CT but abnormal on pentetreotide imaging. In 13 patients, normal findings were noted on both PET/CT and pentetreotide imaging. Kaplan-Meier analysis demonstrated a significant survival advantage for patients who had normal findings on PET/CT in comparison with abnormal PET/CT findings (P = .01). Patients with normal findings on indium In 111 pentetreotide imaging had a higher but insignificant survival advantage over those with abnormal results on pentetreotide imaging (P = .08). Conclusion: For evaluation of NETs, PET/CT and indium In 111 pentetreotide are complementary. Increased metabolic activity in tumor cells is reflected by abnormalities on PET/CT. Patients who had abnormal PET/CT findings had a generally poorer prognosis and a more rapid clinical deterioration than those with normal PET/CT findings.

AB - Objective: To determine whether positron emission tomography/computed tomography (PET/CT) and indium In 111 pentetreotide, individually or collectively, predict the outcome of patients with neuroendocrine tumors (NETs). Methods: Between July 31, 2002, and May 4, 2007, 29 patients with previously diagnosed NETs underwent both PET/CT and indium In 111 pentetreotide imaging at our institution. The images were evaluated for the presence of abnormalities. Clinical outcomes were classified as survival without major morbidities, survival with severe complications of disease, or death. Time to outcome was measured in months from the imaging date to outcome. Kaplan-Meier survival curves were calculated in which patient outcome was compared with results on PET/CT and indium In 111 pentetreotide imaging. Results: Of the 29 patients, 9 had abnormalities on both PET/CT and indium In 111 pentetreotide imaging. Two patients had abnormal findings on PET/CT but normal findings on pentetreotide imaging. In 5 patients, findings were normal on PET/CT but abnormal on pentetreotide imaging. In 13 patients, normal findings were noted on both PET/CT and pentetreotide imaging. Kaplan-Meier analysis demonstrated a significant survival advantage for patients who had normal findings on PET/CT in comparison with abnormal PET/CT findings (P = .01). Patients with normal findings on indium In 111 pentetreotide imaging had a higher but insignificant survival advantage over those with abnormal results on pentetreotide imaging (P = .08). Conclusion: For evaluation of NETs, PET/CT and indium In 111 pentetreotide are complementary. Increased metabolic activity in tumor cells is reflected by abnormalities on PET/CT. Patients who had abnormal PET/CT findings had a generally poorer prognosis and a more rapid clinical deterioration than those with normal PET/CT findings.

UR - http://www.scopus.com/inward/record.url?scp=75549092151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75549092151&partnerID=8YFLogxK

U2 - 10.4158/EP08318.ORR1

DO - 10.4158/EP08318.ORR1

M3 - Article

C2 - 19491080

AN - SCOPUS:75549092151

VL - 15

SP - 521

EP - 527

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 6

ER -